CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 119 enrolled
Drug / intervention
Atomoxetine +1 moredrug
Likely dose
Atomoxetine 40mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00628394
NCT00628394Phase 4Completed
CompareCT.gov

Cognitive Treatments in Schizophrenia

University of Texas Southwestern Medical Center·interventional·Posted Mar 5, 2008·Updated Sep 25, 2020

In Brief

A Phase 4 clinical trial evaluating Atomoxetine and Placebo for Cognition in Schizophrenia. Completed, enrolled 119 participants across 1 site.

Detailed Summary

This research is being done because people with schizophrenia often have problems with thinking including learning, remembering, paying attention, and problem solving. During this study, we will test if cognitive remediation (computer games made to improve thinking), used along with a drug called atomoxetine, may help the problems in thinking as well as some of the symptoms of schizophrenia.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCognition in Schizophrenia
CountriesUnited States
CollaboratorsNational Institute of Mental Health (NIMH), Stanley Medical Research Institute

Timeline

Phase 4CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 5, 2008
Enrollment StartSep 1, 2003
Primary CompletionFeb 1, 2011
TodayJul 2, 2026
Enrollment to primary: 7.4 yearsPosted 18.3 years ago

Interventions

Atomoxetinedrug

40mg 2po qam

Placebodrug

40mg 2po qam